Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma

Abstract Background The efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy have been presented and evaluated in previously published TD-NICE study. However, the long-term impacts of patients who received tislelizumab plus chemotherapy followed by surgery were not o...

Full description

Bibliographic Details
Published in:	BMC Cancer
Main Authors:	Yajie Mao, Zhiyuan Gao, Yichen Sun, Changjian Shao, Hongtao Duan, Xiaolong Yan
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Esophageal cancer Neoadjuvant chemoimmunotherapy Survival analysis
Online Access:	https://doi.org/10.1186/s12885-025-14686-9

Similar Items

Editorial: The role of adjuvant and neoadjuvant therapy in resectable esophageal cancer
by: Xiaokun Li, et al.
Published: (2025-09-01)

Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
by: Yue Kong, et al.
Published: (2024-07-01)

Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma
by: Likun Liu, et al.
Published: (2025-08-01)

Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials
by: Tao Luo, et al.
Published: (2025-08-01)

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study
by: Na Zhou, et al.
Published: (2024-12-01)

CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients
by: Weibo Kong, et al.
Published: (2024-12-01)

Case report: Watch-and-wait strategy in resectable esophageal cancer following neoadjuvant chemoimmunotherapy: a case series
by: Lingyu Tan, et al.
Published: (2025-01-01)

Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis
by: Yao Zhang, et al.
Published: (2024-05-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

Pathologic complete response after neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Endoscopic characteristics and implications
by: Peng Yuan, et al.
Published: (2025-01-01)

Comparison of single-port inflatable mediastinoscopic esophagectomy and thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy
by: Kaishang Zhang, et al.
Published: (2025-07-01)

Neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma with non-regional cervical lymph node metastasis: a retrospective pilot study
by: Chufeng Zeng, et al.
Published: (2025-09-01)

Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study
by: Jiazhen Chen, et al.
Published: (2025-08-01)

Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study
by: Shu-Han Xie, et al.
Published: (2024-02-01)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
by: Yulong Chen, et al.
Published: (2023-09-01)

Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma
by: Guozhen Yang, et al.
Published: (2024-05-01)

Strategies of neoadjuvant therapy in esophageal cancer: a study on the effects of treatment frequency and surgery interval
by: Huilai Lv, et al.
Published: (2025-10-01)

Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial
by: Jincheng Guo, et al.
Published: (2025-04-01)

Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma
by: Jun-Peng Lin, et al.
Published: (2025-08-01)

Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial
by: Zhiyuan Gao, et al.
Published: (2025-08-01)

Clinical efficacy of different neoadjuvant therapies for resectable esophageal squamous cell carcinoma
by: Xiaoyang Wang, et al.
Published: (2025-06-01)

A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
by: Hongtao Duan, et al.
Published: (2024-07-01)

Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma
by: Haibo Cai, et al.
Published: (2024-12-01)

Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study
by: Ning‐Ning Kang, et al.
Published: (2024-03-01)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
by: Zhi Zhang, et al.
Published: (2022-10-01)

Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in Tibet
by: Xizhao Sui, et al.
Published: (2025-04-01)

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma
by: Zhen Wang, et al.
Published: (2022-06-01)

Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma
by: Ye Wang, et al.
Published: (2024-04-01)

Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
by: Chengzhi Ding, et al.
Published: (2023-12-01)

Neoadjuvant immunochemotherapy for resectable esophageal cancer: A study on efficacy and safety
by: Xiaomin Wang, et al.
Published: (2025-04-01)

Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study)
by: Hai-Yu Zhou, et al.
Published: (2020-07-01)

A clinical trial of neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma
by: Kazem Anvari, et al.
Published: (2015-01-01)

Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes
by: Peng Song, et al.
Published: (2025-07-01)

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer
by: Baihua Zhang, et al.
Published: (2023-01-01)

Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma
by: Xiao Liu, et al.
Published: (2024-04-01)

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial
by: Jinsong Yang, et al.
Published: (2023-03-01)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
by: Liang Shi, et al.
Published: (2022-10-01)

Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China
by: Jinxin Xu, et al.
Published: (2024-02-01)

Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study
by: Yuchen Wang, et al.
Published: (2025-01-01)

A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma
by: Udit Nindra, et al.
Published: (2023-05-01)